Methylene Blue Capsule Indications
Methylene blue capsules are FDA-approved specifically for the treatment of acquired methemoglobinemia in both pediatric and adult patients. 1
Primary Indication: Acquired Methemoglobinemia
Methylene blue functions as an oxidation-reduction agent that reduces methemoglobin (MetHb) back to functional hemoglobin by accepting electrons from NADPH and converting to leukomethylene blue, which then reduces the ferric (3+) state back to the ferrous (2+) state in red blood cells 2.
When to Treat with Methylene Blue
Administer methylene blue when methemoglobin levels exceed 20-30% or when patients are symptomatic at lower levels, particularly in those with:
- Cardiovascular disease
- Significant anemia
- Carbon monoxide poisoning
- Respiratory compromise 2
The standard dosing is 1-2 mg/kg IV over 5-30 minutes, with effects typically seen within one hour 2, 1.
Critical Contraindications
Methylene blue is absolutely contraindicated in patients with G6PD deficiency because it can paradoxically worsen methemoglobinemia and cause severe hemolytic anemia 2, 1. Ideally, test all patients for G6PD deficiency before administration; in emergencies, obtain a family history of G6PD deficiency 2.
Avoid concomitant use with serotonergic drugs (SSRIs, SNRIs, MAOIs) and opioids due to risk of potentially fatal serotonin syndrome, as methylene blue acts as a potent monoamine oxidase inhibitor 2, 1.
Important Safety Considerations
High-Risk Populations Requiring Caution:
- Pregnant women: Concerns for teratogenicity and intestinal atresia 2
- Premature infants: Risk of hemolysis even without G6PD deficiency 2
- Renal failure patients: Use single dose only; delayed clearance increases toxicity risk 2, 1
- Anesthetized patients: May cause systemic and pulmonary hypertension through guanylate cyclase inhibition 2
Dosing Limits
Do not exceed 7 mg/kg total dose as toxic levels are reached beyond this threshold, with increased risk of worsening methemoglobinemia 2.
Alternative Indications (Off-Label)
While the FDA-approved indication is solely for acquired methemoglobinemia, research evidence suggests potential uses in:
- Septic shock with vasopressor-resistant hypotension 3
- Post-cardiac arrest vasoplegia 4
- Chromoendoscopy for colonoscopy 5
- Postoperative pain management after hemorrhoid surgery 6
However, these remain investigational and are not FDA-approved indications. The evidence for psychiatric uses 7, 8 and oral mucositis 9 is preliminary and should not guide routine clinical practice.
Common Pitfalls to Avoid
- Do not use in G6PD deficiency - this is the most critical error that can be fatal
- Screen for serotonergic drug use before administration to prevent serotonin syndrome
- Do not give repeat doses beyond 2 total doses without considering alternative treatments like exchange transfusion 2, 1
- Monitor for rebound methemoglobinemia after treatment, particularly with long-acting oxidants like dapsone, which may require repeat dosing every 6-8 hours for 2-3 days 2